arrow
A

Andrew L. Pecora

hackensack university medical center
H指数:36
被引数:6,759

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Associations Between Anxiety or Depression Diagnosis and Immune Checkpoint Inhibitor Outcomes

焦虑或抑郁症诊断与免疫检查点抑制剂疗效的关联

2025-11-020
OAAI
Establishing Distinct Cytokine Signatures Differentiating between Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Chip Using Bone Marrow RNA or Cell-Free RNA (cfRNA)

建立区分急性髓系白血病、骨髓增生异常综合征和CHIP的特异性细胞因子特征,使用骨髓RNA或游离RNA(cfRNA)。

BLOOD
IF23.1
2024-11-050
PRE
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study

个体化新抗原治疗mRNA-4157 (V940) 联合pembrolizumab与pembrolizumab单药治疗黑色素瘤 (KEYNOTE-942): 一项随机2b期研究

LANCET
IF88.5
2024-02-01121
PRE
mRNA-4157 (V940) individualized neoantigen therapy plus pembrolizumab vs pembrolizumab in high-risk resected melanoma: Clinical efficacy and correlates of response

mRNA-4157 (V940) 个体化新抗原治疗联合帕博利珠单抗与帕博利珠单抗治疗高危黑色素瘤: 临床疗效和反应相关性

2023-10-011
OA
The impact of immunosuppressive agents on immune checkpoint inhibitor efficacy in patients with advanced melanoma: A real-world, multicenter, retrospective study
CANCER
IF5.1
2023-03-237
PRE
Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma
2021-03-2214
OA
Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study
2021-01-1430
OAAI
Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study
2020-10-01211
OAAI